MedTrace Logo

Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy

NCT03239535 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-08-04

No results posted yet for this study

Summary

The clinical trial aims to study the safety and efficacy of adult allogeneic mesenchymal stem cells for the treatment of critical limb ischemia.

Conditions

  • Critical Limb Ischemia

Interventions

BIOLOGICAL

Mesenchymal stem cells

Intramuscular injection

BIOLOGICAL

Normal saline

Intramuscular injection

Sponsors & Collaborators

  • Federal Research Clinical Center of Federal Medical & Biological Agency, Russia

    lead OTHER_GOV

Principal Investigators

  • Vladimir P Baklaushev, MD, PhD · Deputy Director

  • Pavel Yu Orekhov, MD, PhD · Vascular Surgeon

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2018-08-01
Completion
2018-11-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03239535 on ClinicalTrials.gov